# CJC-1295 Buy — Independent dossier on a halted GHRH analog and its supply landscape > What the published research, FDA Pharmacy Compounding Advisory Committee briefings, and WADA standards say about CJC-1295 — a long-acting GHRH analog whose Phase 2 program was terminated in 2006 and which the FDA placed in 503A Category 2 in 2023. An independent record of what published science, FDA committee briefings, and anti-doping authorities say about a research peptide that was never approved, whose only Phase 2 trial was halted in 2006, and whose U.S. supply remains restricted. ## The short version CJC-1295 is a synthetic version of the hormone that tells your pituitary gland to release growth hormone. Unlike the natural version, which clears from the bloodstream in about seven minutes, CJC-1295 DAC — the long-acting form — stays active for nearly a week by hitching a ride on a blood protein called albumin. The result is days of elevated growth hormone and IGF-1, the downstream signal that drives tissue repair and metabolism. It was never approved by the FDA. A Phase 2 clinical trial was terminated in 2006. The FDA's compounding advisory committee reviewed it in 2024 and did not recommend it for pharmacy compounding. It is prohibited by the World Anti-Doping Agency at all times. This dossier catalogs the peer-reviewed evidence: what the compound does in the lab, what the Phase 1 human data actually show, and where the regulatory record stands today. It also covers [what people using it in research settings report](/effects) — both the effects they describe and the cautions that matter. ## What CJC-1295 is, in one paragraph CJC-1295 is a 30-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH) developed in the early 2000s by ConjuChem Biotechnologies. It is built on the first 29 amino acids of human GHRH with four protective substitutions — D-Ala at position 2, Gln at 8, Ala at 15, and Leu at 27 — that resist enzymatic degradation. The defining structural feature is a 31st modification: a maleimidopropionic acid group at the C-terminus that covalently bonds to the free thiol on Cys34 of circulating serum albumin after subcutaneous injection [1]. That albumin tether is what makes CJC-1295 long-acting; the mean plasma half-life in healthy adults is between 5.8 and 8.1 days, against the roughly seven-minute half-life of native GHRH [2]. The non-DAC version — sometimes sold as 'CJC-1295 without DAC' or 'modified GRF (1-29)' — omits the maleimide group and has a plasma half-life of approximately 30 minutes [8]. The two are pharmacokinetically distinct and frequently conflated in supplier copy. ## Why this site exists The phrase 'CJC-1295 buy' is a high-frequency search query. The pages that rank for it tend to be vendor product listings, not editorial summaries — which means anyone looking for the regulatory, clinical, and analytical record of the compound has to assemble it themselves from primary literature. This dossier is that assembly. It catalogs what peer-reviewed studies, FDA Pharmacy Compounding Advisory Committee briefings, World Anti-Doping Agency standards, and forensic mass-spectrometry papers actually say about CJC-1295 — its mechanism, its halted clinical program, its current regulatory status, and the supply landscape that has formed around it. The domain modifier 'buy' is editorial framing. It locates this publication relative to a particular search intent. It is not a claim about services this site offers. The site does not sell CJC-1295, does not facilitate its purchase, does not direct readers to vendors, and is not affiliated with any pharmacy, compounder, research-chemical supplier, or clinic. It is an independent editorial record. ## The regulatory record in five facts **One.** CJC-1295 is not approved by the U.S. Food and Drug Administration or by any other major regulator for any human indication. It has never been approved. **Two.** The only Phase 2 trial — NCT00267527, a 192-participant study in HIV-associated visceral adiposity sponsored by ConjuChem Biotechnologies — was terminated in October 2006 after a participant died from an acute coronary event approximately two hours after the eleventh weekly dose. An independent review attributed the event to pre-existing undiagnosed coronary artery disease and judged it unrelated to study drug, but the program was halted and primary efficacy endpoints were never published [7]. **Three.** In 2023, the FDA placed CJC-1295 in Section 503A Category 2 — substances not approved for routine compounding pending FDA review — which directly restricted the channels through which it can be lawfully supplied through traditional U.S. compounding pharmacies [13]. **Four.** At the October 29, 2024 meeting of the FDA Pharmacy Compounding Advisory Committee, members reviewed pharmacology, safety, and historical use data on CJC-1295 (five chemical forms across DAC and non-DAC variants) and did not recommend inclusion on the 503A bulk drug substances list. A follow-up briefing on December 4, 2024 consolidated public comment, manufacturer evidence submissions, and adverse-event signal review and reiterated insufficient evidence to support routine 503A access [13, 17]. **Five.** The World Anti-Doping Agency lists CJC-1295 on the 2025 Prohibited List under Section S2 — Peptide Hormones, Growth Factors, Related Substances, and Mimetics — at all times, both in-competition and out-of-competition. For any athlete subject to the WADA Code, possession alone constitutes an Anti-Doping Rule Violation under Article 2.6 [16]. ## The clinical record in three lines The published human evidence base for CJC-1295 is narrow. One Phase 1 pharmacokinetic and pharmacodynamic study in healthy adults established that single subcutaneous doses of 30 to 250 μg/kg produced mean plasma growth hormone elevations of two- to ten-fold for at least six days and mean IGF-1 elevations of 1.5- to three-fold for nine to eleven days; multiple-dose cohorts sustained IGF-1 elevation up to 28 days [2]. A companion paper from the same program demonstrated that GH secretion remained pulsatile during continuous CJC-1295 stimulation rather than being abolished, with trough GH levels rising approximately 7.5-fold while normal pulse architecture was preserved [6]. There are no published long-term human efficacy or safety randomized controlled trials. The Phase 2 program in HIV-associated visceral adiposity was the only registered clinical-stage efficacy study, and it was terminated before primary endpoint publication [7]. ## Where to read further The [research page](/research) walks through the mechanism, the published Phase 1 data, the pulsatility findings, and the comparator literature on the closely related FDA-approved GHRH analog tesamorelin. The [dosage page](/dosage) is a research-context summary only — doses studied in animal models and the published Phase 1 cohort, with no prescriptive dosing guidance. The [FAQ page](/faq) answers the questions that recur in search around buying, legality, vendor verification, the DAC versus non-DAC distinction, and what the WADA listing means in practice. The [references page](/references) is the full citation list — peer-reviewed papers, ClinicalTrials.gov entries, FDA briefing materials, and the WADA prohibited list — sortable by year and source category. The [about page](/about) explains who publishes this dossier and the editorial standards applied. --- An independent editorial record of what the published literature, the FDA, and WADA say about CJC-1295.